CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 140 filers reported holding CLOVIS ONCOLOGY INC in Q1 2016. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $9,600,000 | -48.9% | 500,000 | -6.9% | 0.16% | -42.2% |
| Q4 2015 | $18,794,000 | -73.9% | 536,967 | -31.3% | 0.28% | -71.3% |
| Q3 2015 | $71,893,000 | +9.0% | 781,778 | +4.1% | 0.98% | +5.0% |
| Q2 2015 | $65,983,000 | +35.3% | 750,823 | +14.3% | 0.94% | +30.0% |
| Q1 2015 | $48,768,000 | -6.1% | 656,992 | -29.2% | 0.72% | -2.0% |
| Q4 2014 | $51,961,000 | +44.9% | 927,839 | +17.4% | 0.73% | +38.8% |
| Q3 2014 | $35,849,000 | +9.6% | 790,335 | +0.1% | 0.53% | +4.1% |
| Q2 2014 | $32,711,000 | -59.3% | 789,933 | -31.9% | 0.51% | -61.0% |
| Q1 2014 | $80,328,000 | +137.5% | 1,159,623 | +106.6% | 1.30% | +95.9% |
| Q4 2013 | $33,823,000 | +64.6% | 561,184 | +66.0% | 0.66% | +42.5% |
| Q3 2013 | $20,547,000 | +45.4% | 338,059 | +60.2% | 0.47% | +41.2% |
| Q2 2013 | $14,131,000 | – | 210,970 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
| Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
| Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
| Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
| HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
| PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
| NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
| PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
| Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |